Current Treatment Protocols:

We have treated hundreds of patients with PAH with long-term intravenous prostacyclin, treprostinil, sildenafil, tadalafil, bosentan, ambrisentan, iloprost, riociguat, macitentan, and more. We accept referrals from all sources and welcome any interest or questions from health-care workers and from the general public.


LOOK

     A Phase 3 trial of bardoxolone for patients with PAH is just starting.

     A trial of a new oral prostacyclin receptor agonist (oral selexipag) for patients with PAH has been completed.

     A trial of a new drug (oral ASK-1 inhibitor) for patients with PAH is no longer enrolling, patients remain on the study drug.

     Exercise training (rehabilitation) trial: Tune in soon for more info.

                  ...and more!



 

Summary of Research Trials at Harbor-UCLA

 

TRIAL

SPONSOR

PLACEBO

PRIMARY ENDPOINT

START DATE

Bardoxolone methyl oral

Reata Pharmaceuticals

Yes

6-minute walk distance

Enrolling

Ubenimex (LTB4 inhibitor)

Eiger BioPharmaceuticals

Yes

Pulmonary Vascular Resistance (PVR)

Enrolling

Inhaled Tyvaso combined with oral beraprost (prostanoids)

United Therapeutics

Yes

Time to clinical worsening (events)

Enrolling

Endothelin antagonist macitentan (added to sildenafil)

Actelion

Yes (1 in 2)

clinical worsening

Completed in 2009. Highly successful

Oral Prostanoid

Lung Biotechnology

yes

6-minute walk

Completed

Ambrisentan, tadalafil, or both

Gilead Sciences

No

Time to clinical failure (events)

Completed in 2016. Highly successful

Exercise rehabilitation (see link above)

NIH/Harbor-UCLA

Yes

multiple

Pilot study completed

Scleroderma PAH screening

Harbor-UCLA

Yes

multiple

Ongoing

 

 



Conventional
PULMONARY ARTERIAL HYPERTENSION TREATMENT

       All patients are given an in-depth medical evaluation and counseled on the risks and benefits of prostacyclin in PAH.

       Initiation of prostacyclin takes approximately two days as an inpatient, and patients are usually ready to return to progressive activities upon discharge. While patients are hospitalized, their families and/or supporting members will be instructed on the use of prostacyclin, how to administer the drug, and what to do in case of an emergency.


For more information on any of the above trials, call our research coordinator, Joy at 310-222-3560




This page has been viewed times